StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Price Performance

NERV opened at $2.13 on Monday. The firm has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $2.60. Minerva Neurosciences has a fifty-two week low of $2.06 and a fifty-two week high of $13.49. The company has a market cap of $14.90 million, a price-to-earnings ratio of -4.84 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.